Please sign in to follow a disease.
Relapsing polychondritis
MONDO:0019125A rare, clinically heterogeneous, multisystemic inflammatory disease characterized by inflammation of the cartilage and proteoglycan rich structures leading to cartilage damage with joint, ocular and cardiovascular involvement.
Also known as: chronic atrophic polychondritis, recurrent polychondritis
14 clinical trials for this condition and its sub-types, 3 tagged with Relapsing polychondritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for rare cartilage disease: five drugs put to the test
Disease control Recruiting nowThis study tests five different standard immune-suppressing drugs to see which works best for controlling relapsing polychondritis, a rare disease that causes painful inflammation of cartilage. About 20 adults will receive one of the drugs and be monitored for 26 weeks. The goal …
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Massive study aims to unlock mysteries of rare blood vessel disease
Knowledge-focused Recruiting nowThis study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New study aims to unravel rare cartilage disease
Knowledge-focused Recruiting nowThis study follows 100 people with relapsing polychondritis, a rare disease that causes repeated inflammation of cartilage in the ears, nose, and airways. Researchers will collect medical history and survey data to learn how the disease develops. The goal is to better understand …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC